Pharmacological Properties of Bergapten: Mechanistic and Therapeutic Aspects

Abstract

Bergapten (BP) or 5-methoxypsoralen (5-MOP) is a furocoumarin compound mainly found in bergamot essential oil but also in other citrus essential oils and grapefruit juice. This compound presents antibacterial, anti-inflammatory, hypolipemic, and anticancer effects and is successfully used as a photosensitizing agent. The present review focuses on the research evidence related to the therapeutic properties of bergapten collected in recent years. Many preclinical and in vitro studies have been evidenced the therapeutic action of BP; however, few clinical trials have been carried out to evaluate its efficacy. These clinical trials with BP are mainly focused on patients suffering from skin disorders such as psoriasis or vitiligo. In these trials, the administration of BP (oral or topical) combined with UV irradiation induces relevant lesion clearance rates. In addition, beneficial effects of bergamot extract were also observed in patients with altered serum lipid profiles and in people with nonalcoholic fatty liver. On the contrary, there are no clinical trials that investigate the possible effects on cancer. Although the bioavailability of BP is lower than that of its 8-methoxypsoralen (8-MOP) isomer, it has fewer side effects allowing higher concentrations to be administered. In conclusion, although the use of BP has therapeutic applications on skin disorders as a sensitizing agent and as components of bergamot extract as hypolipemic therapy, more trials are necessary to define the doses and treatment guidelines and its usefulness against other pathologies such as cancer or bacterial infections.

Targeting Ras-ERK cascade by bioactive natural products for potential treatment of cancer: an updated overview

“…Cancer is the abnormal and anarchic development of cells, with the potential to invade or spread to various parts of the body [ 1 , 2 ]. Cancer can occur in any part of the body, and cancer cells can invade other organs in different ways (neighbourhood invasion, hematogenous or lymphatic) [ 3 – 5 ]. In 2020, there have been an estimated 18.1 million cancer cases worldwide.…”

Anticancer potential of alkaloids: a key emphasis to colchicine, vinblastine, vincristine, vindesine, vinorelbine and vincamine

“…The anticancer properties of natural alkaloids have been used traditionally and in contemporary medicine to advance cost-effective overall cancer management. For cancer treatment, researching a natural substance represents an attractive strategy [ 139 ]. As plant-based drug development is advancing due to its proven efficacy and cost-effectiveness, plant alkaloids are the most promising.…”

Recent advances and limitations of mTOR inhibitors in the treatment of cancer

“…Tumor genomic testing has evolved, from several biomarkers to extensive panels—allowing the analysis of all mutations that can be acted upon by targeted therapies, and even more, biomarkers that allow patients to be included in clinical trials for treatments not yet approved. Regarding the therapeutic targets in cancer, research in this field has led to the approval of many drugs in recent years and there are many other molecules still in clinical or preclinical studies, so we can expect complex changes in therapeutic standards in cancer in the near future [ 72 ].…”